
According to findings reported during the 2018 Gastrointestinal Cancers Symposium, a weekly dose-escalation strategy of regorafenib (Stivarga) beginning at 80 mg and ending at 160 mg was found to be superior than the previously standard starting dose of 160 mg in patients with metastatic colorectal cancer.








